Ionization-specific prediction of blood-brain permeability.

This study presents a mechanistic QSAR analysis of passive blood-brain barrier permeability of drugs and drug-like compounds in rats and mice. The experimental data represented in vivo log PS (permeability-surface area product) from in situ perfusion, brain uptake index, and intravenous administration studies. A data set of 280 log PS values was compiled. A subset of 178 compounds was assumed to be driven by passive transport that is free of plasma protein binding and carrier-mediated effects. This subset was described in terms of nonlinear lipophilicity and ionization dependences, that account for multiple kinetic and thermodynamic effects: (i) drug's kinetic diffusion, (ii) ion-specific partitioning between plasma and brain capillary endothelial cell membranes, and (iii) hydrophobic entrapment in phospholipid bilayer. The obtained QSAR model provides both good statistical significance (RMSE < 0.5) and simple physicochemical interpretations (log P and pKa), thus providing a clear route towards property-based design of new CNS drugs.

[1]  V. Hruby,et al.  Improved bioavailability to the brain of glycosylated Met-enkephalin analogs , 2000, Brain Research.

[2]  Y. Sugiyama,et al.  Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. , 1996, The Journal of pharmacology and experimental therapeutics.

[3]  T. Tsuruo,et al.  Contribution of P‐glycoprotein to efflux of ramosetron, a 5‐HT3 receptor antagonist, across the blood‐brain barrier , 2002, The Journal of pharmacy and pharmacology.

[4]  C. L. Graff,et al.  Variable modulation of opioid brain uptake by P-glycoprotein in mice. , 2004, Biochemical pharmacology.

[5]  Buchwald,et al.  Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. , 1999, Advanced drug delivery reviews.

[6]  Q. Smith,et al.  Characterization of the blood–brain barrier choline transporter using the in situ rat brain perfusion technique , 2001, Journal of neurochemistry.

[7]  Irene Luque Ruiz,et al.  QSAR models based on isomorphic and nonisomorphic data fusion for predicting the blood brain barrier permeability , 2007, J. Comput. Chem..

[8]  Christophe Rousselle,et al.  Development of an In Situ Mouse Brain Perfusion Model and its Application to mdr1a P-Glycoprotein-Deficient Mice , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  S. Yamada,et al.  Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system. , 1997, The Journal of pharmacology and experimental therapeutics.

[10]  R. Spector Transport of amantadine and rimantadine through the blood-brain barrier. , 1988, The Journal of pharmacology and experimental therapeutics.

[11]  N. Kawai,et al.  Glutamine transport at the blood–brain and blood–cerebrospinal fluid barriers , 2003, Neurochemistry International.

[12]  Gary M. Pollack,et al.  Effect of mdr1a P-Glycoprotein Gene Disruption, Gender, and Substrate Concentration on Brain Uptake of Selected Compounds , 2001, Pharmaceutical Research.

[13]  T. Terasaki,et al.  Involvement of organic anion transporters in the efflux of uremic toxins across the blood–brain barrier , 2006, Journal of neurochemistry.

[14]  W. Oldendorf,et al.  Transient blood-brain barrier passage of polar compounds at low pH. , 1994, American Journal of Physiology.

[15]  D. E. Clark,et al.  In Silico Predictions of Blood-Brain Barrier Penetration: Considerations to “Keep in Mind” , 2005, Journal of Pharmacology and Experimental Therapeutics.

[16]  A. Leo,et al.  Substituent constants for correlation analysis in chemistry and biology , 1979 .

[17]  N. Abbott Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. , 2004, Drug discovery today. Technologies.

[18]  Harpreet S. Chadha,et al.  Molecular Factors Influencing Drug Transfer across the Blood‐Brain Barrier , 1997, The Journal of pharmacy and pharmacology.

[19]  M. Abraham Application of solvation equations to chemical and biochemical processes , 1993 .

[20]  Remigijus Didziapetris,et al.  Fragmental Methods in the Design of New Compounds. Applications of The Advanced Algorithm Builder , 2002 .

[21]  Yanfeng Wang,et al.  The Simultaneous Estimation of the Influx and Efflux Blood-Brain Barrier Permeabilities of Gabapentin Using a Microdialysis-Pharmacokinetic Approach , 1996, Pharmaceutical Research.

[22]  Prabha Garg,et al.  In Silico Prediction of Blood Brain Barrier Permeability: An Artificial Neural Network Model , 2006, J. Chem. Inf. Model..

[23]  Andreas Klamt,et al.  Prediction of Blood-Βrain Partitioning and Human Serum Albumin Binding Based on COSMO-RS σ-Moments , 2007, J. Chem. Inf. Model..

[24]  P. Riederer,et al.  The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood–brain barrier and exhibits anticonvulsive effects , 2004, British journal of pharmacology.

[25]  Bahram Hemmateenejad,et al.  Accurate prediction of the blood–brain partitioning of a large set of solutes using ab initio calculations and genetic neural network modeling , 2006, J. Comput. Chem..

[26]  Y. Sawada,et al.  Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. , 2000, American journal of physiology. Heart and circulatory physiology.

[27]  F. Tse,et al.  Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat , 1998, Biopharmaceutics & drug disposition.

[28]  Alexandre Varnek,et al.  Correlation of blood-brain penetration using structural descriptors. , 2006, Bioorganic & medicinal chemistry.

[29]  D. Mock,et al.  Biotin Transport Through the Blood‐Brain Barrier , 1987, Journal of Neurochemistry.

[30]  S. Yamada,et al.  Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier. , 2000, Life sciences.

[31]  Alex Avdeef,et al.  Absorption and drug development , 2003 .

[32]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[33]  R. Himes,et al.  Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. , 2005, Journal of medicinal chemistry.

[34]  A. Leo,et al.  Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. , 1987, Journal of pharmaceutical sciences.

[35]  Ramamurthi Narayanan,et al.  In silico ADME modelling: prediction models for blood-brain barrier permeation using a systematic variable selection method. , 2005, Bioorganic & medicinal chemistry.

[36]  T. Kaneko,et al.  Permeability of brain structures and other peripheral tissues to prostaglandins D2, E2 and F2 alpha in rats. , 1992, The Journal of pharmacology and experimental therapeutics.

[37]  Mark L. Lewis,et al.  Predicting Penetration Across the Blood-Brain Barrier from Simple Descriptors and Fragmentation Schemes , 2007, J. Chem. Inf. Model..

[38]  P D Leeson,et al.  Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. , 1997, Journal of medicinal chemistry.

[39]  W H Oldendorf,et al.  Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. , 1971, The American journal of physiology.

[40]  Meihua Tu,et al.  Development of a computational approach to predict blood-brain barrier permeability. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[41]  C. Rousselle,et al.  Screening of Multidrug-Resistance Sensitive Drugs by In Situ Brain Perfusion in P-Glycoprotein-Deficient Mice , 2001, Pharmaceutical Research.

[42]  J. Viña,et al.  Structure of the blood-brain barrier and its role in the transport of amino acids. , 2006, The Journal of nutrition.

[43]  K. Boje,et al.  Blood–brain barrier transport studies of organic guanidino cations using an in situ brain perfusion technique , 2000, Brain Research.

[44]  W. Hass,et al.  Unsymmetrical alkyl aryl thiourea compounds for use as cerebral blood flow tracers. , 1980, The American journal of physiology.

[45]  W. Pardridge The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[46]  M. Abraham,et al.  The use of characteristic volumes to measure cavity terms in reversed phase liquid chromatography , 1987 .

[47]  Juan M. Luco,et al.  QSAR Studies on Blood-Brain Barrier Permeation , 2006 .

[48]  T. Terasaki,et al.  Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. , 1993, The Journal of pharmacology and experimental therapeutics.

[49]  H Kubinyi,et al.  Quantitative structure--activity relationships. 7. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character. , 1977, Journal of medicinal chemistry.

[50]  S. Cisternino,et al.  Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats , 2003, British journal of pharmacology.

[51]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[52]  Q. Smith,et al.  Brain Uptake of Nonsteroidal Anti-Inflammatory Drugs: Ibuprofen, Flurbiprofen, and Indomethacin , 2006, Pharmaceutical Research.

[53]  R. Spector,et al.  Transport of diphenhydramine in the central nervous system. , 1987, The Journal of pharmacology and experimental therapeutics.

[54]  S. Rapoport,et al.  An in situ brain perfusion technique to study cerebrovascular transport in the rat. , 1984, The American journal of physiology.

[55]  W. Geldenhuys,et al.  Cation Transport Specificity at the Blood–Brain Barrier , 2004, Neurochemical Research.

[56]  R. Lipnick Outliers: their origin and use in the classification of molecular mechanisms of toxicity. , 1991, The Science of the total environment.

[57]  V A Levin,et al.  Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.

[58]  Michael H Abraham,et al.  The factors that influence permeation across the blood-brain barrier. , 2004, European journal of medicinal chemistry.

[59]  Y. Sugiyama,et al.  Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. , 1997, The Journal of pharmacology and experimental therapeutics.

[60]  I. Tamai,et al.  Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier. , 1999, The Journal of pharmacology and experimental therapeutics.

[61]  G R Wilkinson,et al.  Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. , 1988, The Journal of pharmacology and experimental therapeutics.

[62]  R. Spector Fatty Acid Transport Through the Blood‐Brain Barrier , 1988, Journal of neurochemistry.

[63]  K. Hosoya,et al.  The blood-brain barrier efflux transporters as a detoxifying system for the brain. , 1999, Advanced drug delivery reviews.

[64]  M. Hanano,et al.  Investigation of transport mechanism of pentazocine across the blood-brain barrier using the in situ rat brain perfusion technique. , 2002, Journal of pharmaceutical sciences.

[65]  J. Bourre,et al.  Taurine transport at the blood-brain barrier: an in vivo brain perfusion study , 1995, Brain Research.

[66]  S. Curry,et al.  Brain uptake and biotransformation of remacemide hydrochloride, a novel anticonvulsant. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[67]  Phil Jeffrey,et al.  Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction , 2007, Journal of Pharmacology and Experimental Therapeutics.

[68]  U. Bickel,et al.  How to measure drug transport across the blood-brain barrier , 2011, NeuroRX.

[69]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[70]  W. Pardridge,et al.  Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. , 1990, The Journal of pharmacology and experimental therapeutics.

[71]  C. Rousselle,et al.  Apparent Lack of Mrp1-Mediated Efflux at the Luminal Side of Mouse Blood-Brain Barrier Endothelial Cells , 2003, Pharmaceutical Research.